EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review

Marclesson Santos Alves, Juliana Palácio de Queiroz Ventura Barros, Danielle Calheiros Campelo Maia, Igor Santos Costa iD, Ormando Rodrigues Campos Junior, Howard Lopes Ribeiro Junior iD

Current Oncology · 2026

DOI: 10.3390/curroncol33090536 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2026. Verfasst von Marclesson Santos Alves und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Lung Neoplasms, Hyperpigmentation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazilian National Council for Scientific and Technological Development, INCT-Bio2–Biodescoberta Translacional e Biomodelos.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of targeted therapies has improved outcomes in patients with resected epidermal growth factor receptor-mutated non-small cell lung cancer, but uncommon and persistent dermatologic toxicities remain poorly characterized. We report a 71-year-old woman with resected lung adenocarcinoma harboring an epidermal growth factor receptor exon 21 L858R mutation. Following right upper lobectomy and systematic mediastinal lymph node dissection, pathological staging was pT2aN1M0 (stage IIB). She received four cycles of adjuvant cisplatin plus pemetrexed followed by planned three-year adjuvant Osimertinib. During Osimertinib treatment, she developed a persistent violaceous rash accompanied by progressive cutaneous hyperpigmentation. Osimertinib was temporarily interrupted, and dermatologic evaluation was performed, resulting in partial clinical improvement. Hyperpigmentation, however, persisted during follow-up. Other adverse events included grade 1 diarrhea, transient arthralgia, anorexia, and weight loss. Osimertinib was subsequently resumed and maintained. Nearly two years after surgery, the patient remains free of disease recurrence, with stable pigmentary skin changes. This case highlights an uncommon and prolonged dermatologic manifestation associated with Osimertinib and emphasizes the importance of recognizing atypical cutaneous toxicity to facilitate appropriate management and to facilitate appropriate dermatologic evaluation and individualized management of treatment-related toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsAcrylamidesLung NeoplasmsHyperpigmentationAdenocarcinoma of LungAntineoplastic AgentsHumansIndolesFemaleAgedPyrimidinesErbB ReceptorsMutation

Stichwörter der Autor:innen

EGFR mutationEGFR tyrosine kinase inhibitorL858Radjuvant therapycase reportcutaneous hyperpigmentationdermatologic toxicitynon-small cell lung cancerosimertinibviolaceous rash

Substanzen

IndolesAniline CompoundsosimertinibAcrylamidesPyrimidinesErbB ReceptorsEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil.
  • Argos Patologia, Fortaleza 60175-047, CE, Brazil.
  • Post-Graduate Program in Pathology, Post-Graduate Program in Translational Medicine, Center for Research and Drug Development (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil.

ORCID-Profile: Igor Santos Costa, Howard Lopes Ribeiro Junior

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Brazilian National Council for Scientific and Technological Development
  • INCT-Bio2–Biodescoberta Translacional e Biomodelos
  • PPSUS Innovation—Class 2: Social and Institutional Innovations

Zitieren

APA

Alves, M. S., Ventura Barros, J. P. Q., Maia, D. C. C., Costa, I. S., Campos Junior, O. R., & Ribeiro Junior, H. L. (2026). Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review. Current Oncology. https://doi.org/10.3390/curroncol33090536

Vancouver

Alves MS, Ventura Barros JPQ, Maia DCC, Costa IS, Campos Junior OR, Ribeiro Junior HL. Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review. Current Oncology. 2026. doi:10.3390/curroncol33090536

BibTeX
@article{Alves2026,
  author = {Alves, Marclesson Santos and Ventura Barros, Juliana Palácio de Queiroz and Maia, Danielle Calheiros Campelo and Costa, Igor Santos and Campos Junior, Ormando Rodrigues and Ribeiro Junior, Howard Lopes},
  title = {Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33090536}
}
Kostenlos starten →